Speaking about "The Guardian of Genome". Aprea should be close of announcing top line results for their ARP-246 in treatment of TP53-mutated MDS. Some are expecting news as early as this month. Official primary completion date is still in November 2020.
If the trial is successful news might give IPIX a boost... or not. With IPIX you never know.